|
EFFECT OF LJP 394
OR HIGH DOSE CORTICOSTEROIDS AND CYCLOPHOSPHAMIDE ON ANTI-dsDNA
ANTIBODIES IN SLE PATIENTS
MD Linnik, et al.
Presented at
The 65th Annual Scientific Meeting of the American College of
Rheumatology
San Francisco, California
Nov. 11-15, 2001
THE B-CELL TOLERAGEN LJP-394 REDUCES RENAL FLARES IN PATIENTS WITH
LUPUS NEPHRITIS: A PROSPECTIVE DOUBLE-BLINDED, PLACEBO CONTROLLED
TRIAL
J.A. Tumlin, M. D., et al.
Presented at
The ASN / ISN World Congress of Nephrology 2001
San Francisco, California
Oct. 10-17, 2001
USE
OF MUTATIONS IN DOMAIN 1 AND DOMAIN 4 OF ß2GPI TO DETERMINE
FINE ANTIGENIC SPECIFICITY OF ANTIPHOSPHOLIPID AUTOANTIBODIES
G. Michael Iverson, et al.
Presented at
The 27th Annual Conference of the La Jolla Immunologists
La Jolla, California
Oct. 23 & 24, 2001
Also presented at
The 18th Congress of the International Society on Thrombosis and
Haemostasis
Paris, France
Jul. 6-12, 2001
DIVERGENT GROWTH OF BRANCHED CARBAMATES: INTERMEDIATES FOR CONSTRUCTING
MULTIVALENT PLATFORMS
David S. Jones, et al.
Presented at
The 221st ACS National Meeting
San Diego, California
Apr. 1-5, 200
SYNTHESIS OF A TETRAVALENT CONJUGATE OF THE FIRST DOMAIN OF b2GPI:
SITE SPECIFIC ATTACHMENT OF A PROTEIN TO A MULTIVALENT PLATFORM
David S. Jones, et al.
Presented at
The 221st ACS National Meeting
San Diego, California
Apr. 1-5, 2001
SLE TRIAL SHOWS FEWER RENAL FLARES IN LJP 394-TREATED PATIENTS WITH
HIGH-AFFINITY ANTIBODIES TO LJP 394: 90-05 TRIAL RESULTS
D Alarcon-Segovia, et al.
Presented at
The 6th International Lupus Conference
Barcelona, Spain
Mar. 24-28, 2001
EFFECT OF LJP 394 ON SLE PATIENTS WITH IMPAIRED RENAL FUNCTION
Matthew D Linnik, et al.
Presented at
The 6th International Lupus Conference
Barcelona, Spain
Mar. 24-28, 2001
AFFINITY OF ANTIBODIES FOR LJP 394 INFLUENCES PHARMACODYNAMIC RESPONSE
TO LJP 394 IN SLE PATIENTS
Matthew D. Linnik, et al.
Presented at
The 6th International Lupus Conference
Barcelona, Spain
Mar. 24-28, 2001
A NOVEL THERAPEUTIC APPROACH FOR TREATING ANTIPHOSPHOLIPID SYNDROME
BASED ON TOLERIZING ANTI-ß2-GPI B CELLS
Matthew D. Linnik, et al.
Presented at the 26th International Stroke Conference
Fort Lauderdale, Florida
Feb. 14-16, 2001
|
SYNTHESIS OF MULTIVALENT
CARBONATE ESTERS BY DIVERGENT GROWTH OF BRANCHED CARBAMATES
DS Jones, et al.
Published in
Tetrahedron Letters
2001 42: 2069-2072
CLINICAL AND PHARMACOLOGICAL
EXPERIENCE WITH LJP-394
Wallace DJ
Published in
Expert Opinion on Investigational Drugs
2001 Volume 10: pp. 111-117
BIOSTABILITY AND PHARMACOKINETICS
OF LJP 920, AN OCTAMERIC GAL (a1-3) GAL CONJUGATE FOR THE INHIBITION
OF XENOTRANSPLANTATION REJECTION
Lee Jia, et al.
Published in Journal of Pharmacy and Pharmacology
53 (2001) 999-1005.
IDENTIFICATION
OF A PEPTIDE THAT PROTECTS THE HUMAN
ACETYLCHOLINE RECEPTOR AGAINST ANTIGENIC
MODULATION
Luo GX, et al.
Published in the
Journal of Immunological Methods, 2001;251:
177-186
PRE-TREATMENT
AFFINITY FOR LJP 394 INFLUENCES PHARMACODYNAMIC
RESPONSE IN LUPUS PATIENTS
McNeeley PA, et al.
Published in Lupus, 2001;10: 526-532
BETA
2-GLYCOPROTEIN I-DEPENDENT ANTICARDIOLIPIN
ANTIBODIES PREFERENTIALLY BIND THE AMINO
TERMINAL DOMAIN OF BETA 2-GLYCOPROTEIN
1
McNeeley PA, et al.
Published in Thrombosis
and Haemostasis, 2001;86: 590-595
SYNTHESIS
OF LJP 993, A MULTIVALENT CONJUGATE
OF THE N-TERMINAL DOMAIN OF B2GPI AND
SUPPRESSION OF AND ANTI- B2GPI IMMUNE
RESPONSE
Jones DS, et al.
Published in Bioconjugate
Chemistry,
2001;12:1012-1020.
TREATMENT
OF SYSTEMIC LUPUS ERYTHEMATOSUS WITH
LJP394
Richard A. Furie,
Published in
the
Journal of Rheumatology,
2001; 28: 257-265
|